[The coxibs, third generation of non-steroidal anti-inflammatory agents].

The coxibs, specific anti-Cox-2, represent an interesting evolution for the treatment of patients suffering from rheumatic conditions and presenting gastrointestinal ulcer risk. Anti-inflammatory effectiveness is comparable with the other NSAIDs, but the toxicity for the gastrointestinal mucosa is slightly lower. Contra-indications, extradigestive adverse effects and interactions are the same as for any other NSAIDs. Their risks and cost must be taken into account as such as the rheumatic condition of the patient. They may be prescribed to patients presenting a gastrointestinal risk and the relevant cost is reasonable. Pharmacovigilance survey at mid to long term is necessary.